Dr. Adil completed his PharmD, during which he conducted research on COPD patients in the ICU, focusing on prescription evaluation and adverse drug events. Published in 2015 (PMID: 26675667), this work sparked his interest in understanding the root causes of adverse events and preventing them. To gain molecular-level expertise, he pursued a PhD in Clinical & Experimental Therapeutics at the University of Georgia, where he worked on diverse projects and developed strong research skills. He then joined Stanford University for a postdoctoral fellowship, studying human endogenous retroviruses and their influence on chronic inflammation. His current research at LMU-DCOM focuses on how drugs affect immune–endothelial cross-talk, drug interactions, and their broader impact on health, using both in vitro and in silico approaches. Dr. Adil is also passionate about mentoring students and fostering collaborative research.
Current Projects:
- Doxorubicin-Induced Immune and Endothelial Dysregulation (DoxImEnd)
- Mapping CYP450 Modulation in Disease and Drug Response